[Toxoplasmosis serodiagnosis: comparison of Access Toxo IgM II assay compared to Axsym Toxo IgM and Vidas Toxo IgM assays].
The Access Toxo IgM II test (Beckman Coulter Inc) was evaluated on 1,190 samples from toxoplasmosis serology requests, documented seroconversions, umbilical cord blood or venous blood from healthy newborn, and from newborns with congenital toxoplasmosis. Results were compared to those obtained with Vidas (bioMérieux) and Axsym (Abbott) assays, with Isaga as confirmatory technique. Results obtained with the Access test well correlate those with the Vidas (98.3%) and the Axsym (97.6%) assays. Less "bordeline" results are also observed with the Access test (0.22% versus 0.56% and 1.24% with Vidas and Axsym assays respectively). Results obtained from seroconverted patients prove that the Access assay is more sensitive than Vidas and Axsym assays, with respectively 2 and 4 samples detected earlier for 28 cases studied (recently seroconverted patients). Results obtained using prospective samples and with sequential sera obtained from patients with seroconversion clearly demonstrate that Access Toxo IgM II assay is perfectly adapted to toxoplasmosis diagnosis.